RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have signed an exclusive agreement for the clinical-stage anti-immunoglobulin E (IgE) monoclonal antibody, RPT904, designed to treat various allergic conditions.
The agreement grants RAPT global rights, excluding Hong Kong, Taiwan, Macau, and mainland China, to develop and commercialise the therapy.
Go deeper with GlobalData
Under the licence terms, Jemincare is set to obtain an upfront payment of $35m and could earn up to $672.5m in milestone payments, plus royalties on RPT904 sales outside the listed territories.
RPT904 claims to offer a ‘potentially improved’ therapeutic option over omalizumab, which is currently approved for multiple allergic disorders.
RAPT Therapeutics president and CEO Brian Wong said: “We’re delighted to partner with Jemincare and excited by RPT904 and its potential to be a novel best-in-class treatment option for patients with food allergies. Omalizumab’s rapid uptake in food allergy since its approval earlier this year confirms the high unmet need and large opportunity in this growing market.
“RPT904 targets the same clinically validated epitope as omalizumab and combined with extended half-life, gives this molecule a best-in-class profile. We plan to initiate a Phase IIb clinical trial of RPT904 in food allergy in the second half of 2025.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company is targeting the development of RPT904 initially for food allergies. Jemincare is conducting Phase II trials in China for asthma and chronic spontaneous urticaria (CSU).
Jemincare has concluded a Phase I study in China, assessing the pharmacokinetic, safety, and pharmacodynamic profiles of JYB1904, known as RPT904 in RAPT’s designation.
The ongoing Phase II trials in asthma and CSU by Jemincare are set to deliver top-line data in the second half of next year and the first half of 2026, respectively. The antibody has shown promise in early clinical studies for treating food allergies and other allergic inflammatory diseases by targeting free human IgE.
In May 2022, Orion Corporation obtained exclusive rights for the international development and marketing of Jemincare’s non-opioid pain treatment, JMKX000623.
